Our Central Mission Must Be Patient-Centric Innovation: JP Nadda
Union Minister JP Nadda calls for moving discoveries from bench to bedside at the inaugural Bharat Life Sciences Award ceremony in New Delhi.
Union Minister of Health and Family Welfare, Shri Jagat Prakash Nadda, has called upon the nation's life sciences industry to place patient-centric innovation at the very heart of its mission. Speaking at the inaugural Bharat Life Sciences Award (BLSA) held at Vigyan Bhawan, the Minister emphasized that scientific breakthroughs must transcend laboratory success to reach the people who need them most.
From Bench to Bedside: The Mission for Accessibility
Addressing the gathering via video, Shri Nadda highlighted the critical gap between scientific discovery and practical application. He stated that true success in the sector is defined not merely by inventing something in a lab, but by the ability to move those discoveries "from bench to bedside."
"True success is not just inventing in the lab, but taking discoveries from bench to bedside, ensuring high-quality care is accessible, timely and affordable for the last person in the queue," the Minister remarked. He pointed to India's growing bioeconomy and leadership in vaccine manufacturing as evidence of what can be achieved when scientific capability is aligned with public purpose.
The Minister also highlighted the expansion of the Ayushman Bharat PM-JAY scheme, which now provides a ₹5 lakh annual cover to every citizen aged 70 and above, as a cornerstone of India's commitment to inclusive healthcare.
Celebrating Excellence: The Bharat Life Sciences Award Winners
Organized by FICCI and powered by Eli Lilly and Company (India), the inaugural BLSA ceremony recognized outstanding contributions to the field. The awards, supported by ₹7 crore in grant funding, saw over 500 applications evaluated for scientific excellence, innovation, and relevance to the Indian context.
The prestigious winners include:
- Ramanujan Arogya Udaan Samman (Young Scientist): Dr. Vamsee Mallajosyula, National Centre for Biological Sciences (TIFR).
- Charaka Arogya Samman (Innovation for Unmet Patient Needs): Pacify Medical Technologies.
- Sushruta Arogya Samman (Translational and Clinical Advancement): Bharat Serums and Vaccines (BSV-Mankind).
- Nalanda Arogya Vigyan Samman (Institute of Scientific Excellence): BRIC-National Institute of Biomedical Genomics.
- Jivaka Arogya Navpravartan Gaurav (Startup and Academic Innovator): Sciverse Solutions.
- Sarabhai Arogya Drishti Gaurav (Promoting Scientific Ecosystems): Dr. Ratnesh Jain, Institute of Chemical Technology, Mumbai.
Bridging the Gap: Research, Manufacturing, and Regulation
While celebrating successes, experts at the summit identified critical hurdles that must be overcome to transform India into a global innovation powerhouse.
Prof. Gobardhan Das, Member of NITI Aayog, noted that a significant amount of laboratory research fails to reach the production stage. He urged for deeper collaboration between academia and industry, suggesting that the sector must harness the power of Artificial Intelligence to build a more robust pipeline of medicines and vaccines.
Addressing the manufacturing landscape, Shri Manoj Joshi, Secretary of the Department of Pharmaceuticals, noted the encouraging rise in biologics plants. However, he flagged a major dependency: India relies heavily on European suppliers for essential inputs like media, resins, cell lines, and enzymes. He mentioned that the Biopharma Shakti scheme would be instrumental in supporting companies with manufacturing capacity and regulatory approvals abroad.
A Call for Regulatory Integration
Dr. Rajeev Singh Raghuvanshi, Drugs Controller General of India, emphasized that the industry must transition from being a "manufacturing hub" to an "innovation hub." He advised companies to integrate regulatory strategy into their core development processes from the very beginning.
"Regulatory strategy should be part of your core development strategy," Dr. Raghuvanshi advised, citing the successful development of heat-stable and mRNA vaccines during the COVID-19 pandemic as a model for future innovation.